GlaxoSmithKline

PDF document structure and metadata details, including page, catalog, and viewer preferences.

GSK's AReSVi-006 phase III trial shows Arexvy vaccine's cumulative efficacy at 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD over three RSV seasons in adults aged 60+.

GSK's RSV vaccine, Arexvy, shows cumulative efficacy of 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD over three RSV seasons in adults aged 60 and older, including those at increased risk. Safety data aligns with previous results, and GSK will continue to provide long-term follow-up data to inform future revaccination schedules.

New RSV vaccines for older adults, infants, and pregnant women offer protection against severe RSV, which can be life-threatening for high-risk groups. Vaccines include ABRYSVO®, AREXVY®, and mRESVIA® for adults, nirsevimab for infants, and ABRYSVO for pregnant women to protect newborns.

New human H5 influenza cases in California, Marburg vaccine trial in Rwanda, and chem-bio AI model safety considerations.

The Global Drug Device Combination Products Market is projected to reach USD 174.4 billion in 2024 and USD 389.7 billion by 2033 at a CAGR of 9.3%. The US market is expected to grow from USD 59.1 billion in 2024 to USD 125.6 billion by 2033 at a CAGR of 8.7%. Key drivers include technological advancements and rising chronic diseases. Major players include Medtronic, Abbott Laboratories, and Boston Scientific.

ViiV Healthcare plans to triple its HIV prevention therapy supply at not-for-profit prices in low- and middle-income countries by 2026, committing to 2 million doses of long-acting cabotegravir for pre-exposure prophylaxis. This move aims to accelerate HIV prevention in resource-limited, high-burden countries.

ViiV Healthcare's CEO, Deborah Waterhouse, highlights the significance of the long-acting PrEP, CAB LA, in addressing HIV in high-risk populations, particularly young women and girls in Sub-Saharan Africa. The roll-out of CAB LA for PrEP is rapidly expanding in Sub-Saharan Africa and lower-income countries, with 79% of approvals in low- and middle-income countries. ViiV provides CAB LA at a not-for-profit price, facilitated by partnerships with PEPFAR and The Global Fund, and aims to ensure sustainable access through licensing agreements with the Medicines Patent Pool.

mRNA-based pharmaceuticals' licensing agreement deal values grew 800% from 2019 to 2024YTD, reaching $3.8bn in 2024. Global sales for innovator mRNA-based pharmaceuticals were $22bn in 2023, projected to increase to $26.2bn by 2030. Major companies like GSK and Bristol Myers Squibb are investing in mRNA therapeutics, with GSK restructuring a $1.57bn agreement with Curevac and Bristol Myers Squibb collaborating with Repertoire Immune Medicines for up to $1.87bn. The US HHS committed $176m to Moderna for mRNA-based influenza vaccines, highlighting the technology's potential for pandemic preparedness.